HarbourVest Partners LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 116,123 shares of the company’s stock, valued at approximately $2,225,000. HarbourVest Partners LLC owned 0.42% of TransMedics Group as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. UBS Group AG increased its position in TransMedics Group by 28.7% during the third quarter. UBS Group AG now owns 3,025 shares of the company’s stock worth $100,000 after buying an additional 675 shares during the period. Citigroup Inc. increased its position in TransMedics Group by 79.8% during the third quarter. Citigroup Inc. now owns 3,342 shares of the company’s stock worth $111,000 after buying an additional 1,483 shares during the period. Royal Bank of Canada increased its position in TransMedics Group by 148.3% during the second quarter. Royal Bank of Canada now owns 4,318 shares of the company’s stock worth $144,000 after buying an additional 2,579 shares during the period. BNP Paribas Arbitrage SA increased its position in TransMedics Group by 475.0% during the third quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the company’s stock worth $167,000 after buying an additional 4,166 shares during the period. Finally, Ensign Peak Advisors Inc acquired a new position in TransMedics Group during the fourth quarter worth approximately $97,000. 71.75% of the stock is currently owned by institutional investors.
TMDX stock traded up $0.72 on Friday, reaching $28.40. 215,210 shares of the company’s stock were exchanged, compared to its average volume of 429,881. The stock has a fifty day moving average of $24.73 and a 200-day moving average of $21.29. TransMedics Group, Inc. has a twelve month low of $10.00 and a twelve month high of $35.37. The firm has a market cap of $794.63 million, a PE ratio of -16.71 and a beta of 1.79. The company has a quick ratio of 4.47, a current ratio of 5.22 and a debt-to-equity ratio of 0.59.
TMDX has been the topic of several research analyst reports. Canaccord Genuity Group lifted their price target on TransMedics Group from $38.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, March 17th. Cowen boosted their target price on TransMedics Group from $28.00 to $35.00 in a report on Wednesday, May 4th. Zacks Investment Research lowered TransMedics Group from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. JPMorgan Chase & Co. dropped their target price on TransMedics Group from $20.00 to $12.00 in a report on Thursday, February 24th. Finally, Morgan Stanley dropped their target price on TransMedics Group from $22.00 to $15.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $32.29.
In other TransMedics Group news, Director James R. Tobin sold 48,516 shares of the business’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $29.94, for a total transaction of $1,452,569.04. Following the sale, the director now directly owns 350,621 shares in the company, valued at $10,497,592.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP John F. Carey sold 1,500 shares of the business’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $26.85, for a total value of $40,275.00. Following the sale, the vice president now owns 379 shares in the company, valued at $10,176.15. The disclosure for this sale can be found here. Insiders have sold 56,016 shares of company stock worth $1,643,354 in the last ninety days. 10.30% of the stock is currently owned by corporate insiders.
TransMedics Group Profile (Get Rating)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.